Exosomes derived from olfactory mucosa mesenchymal stem cells attenuate cognitive impairment in a mouse model of Alzheimer's disease

Mesenchymal stem cells and exosomes: A novel therapeutic approach for aging

Mesenchymal stem cells (MSCs), a vital component of the adult stem cell repertoire, are distinguished by their dual capacity for self-renewal and multilineage differentiation. The therapeutic effects of MSCs are primarily mediated through mechanisms such as homing, paracrine signaling, and cellular differentiation. Exosomes (Exos), a type of extracellular vesicles (EVs) secreted by MSCs via the paracrine pathway, play a pivotal role in conveying the biological functions of MSCs. Accumulating evidence from extensive research underscores the remarkable anti-aging potential of both MSCs and their Exos. This review comprehensively explores the impact of MSCs and their Exos on key hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, impaired macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis. Furthermore, this paper highlights emerging strategies and novel approaches for modulating the aging process, offering insights into potential therapeutic interventions.

Deep cervical lymphaticovenous anastomosis in Alzheimer's disease: A promising frontier or premature enthusiasm?

Alzheimer's disease (AD) is a progressive neurodegenerative disorder marked by β-amyloid accumulation, tau pathology, and impaired metabolic waste clearance. Recent evidence suggests that meningeal lymphatic vessels (MLVs) contribute significantly to the drainage of cerebrospinal and interstitial fluid. Deep cervical lymphaticovenous anastomosis (LVA), a microsurgical technique designed to enhance this drainage, has been proposed as a potential therapeutic strategy for AD. Preliminary findings from exploratory studies in China indicate possible cognitive and biomarker improvements, but current evidence is limited by small sample sizes, non-randomized designs, and methodological variability. Without standardized protocols and rigorous clinical validation, the broader applicability of LVA remains uncertain. Further investigation through multicenter, controlled trials is essential to objectively assessing its safety, efficacy, and clinical relevance in the management of AD.